key: cord-1025528-f49752bq authors: Bernardes, J. P.; Mishra, N.; Tran, F.; Bahmer, T.; Best, L.; Blase, J. I.; Bordoni, D.; Franzenburg, J.; Geisen, U.; Josephs-Spaulding, J.; Koehler, P.; Kuenstner, A.; Rosati, E.; Aschenbrenner, A. C.; Bacher, P.; Baran, N.; Boysen, T.; Brandt, B.; Bruse, N.; Doerr, J.; Draeger, A.; Elke, G.; Ellinghaus, D.; Fischer, J.; Forster, M.; Franke, A.; Franzenburg, S.; Frey, N.; Friedrichs, A.; Fuss, J.; Glueck, A.; Hamm, J.; Hinrichsen, F.; Hoeppner, M. P.; Imm, S.; Juenker, R.; Kaiser, S.; Kan, Y. H.; Knoll, R.; Lange, C.; Laue, G.; Lier, C.; Lindner, M.; Marinos, G.; Markewitz, R.; Nattermann, J. title: Longitudinal multi-omics analysis identifies responses of megakaryocytes, erythroid cells and plasmablasts as hallmarks of severe COVID-19 trajectories date: 2020-09-18 journal: nan DOI: 10.1101/2020.09.11.20187369 sha: 9cfed87d278276f2edb59618d18a4b4a33707158 doc_id: 1025528 cord_uid: f49752bq The pandemic spread of the potentially life-threatening disease COVID-19 requires a thorough understanding of the longitudinal dynamics of host responses. Temporal resolution of cellular features associated with a severe disease trajectory will be a pre-requisite for finding disease outcome predictors. Here, we performed a longitudinal multi-omics study using a two-centre German cohort of 13 patients (from Cologne and Kiel, cohort 1). We analysed the bulk transcriptome, bulk DNA methylome, and single-cell transcriptome (>358,000 cells, including BCR profiles) of peripheral blood samples harvested from up to 5 time points. The results from single-cell and bulk transcriptome analyses were validated in two independent cohorts of COVID-19 patients from Bonn (18 patients, cohort 2) and Nijmegen (40 patients, cohort 3), respectively. We observed an increase of proliferating, activated plasmablasts in severe COVID-19, and show a distinct expression pattern related to a hyperactive cellular metabolism of these cells. We further identified a notable expansion of type I IFN-activated circulating megakaryocytes and their progenitors, indicative of emergency megakaryopoiesis, which was confirmed in cohort 2. These changes were accompanied by increased erythropoiesis in the critical phase of the disease with features of hypoxic signalling. Finally, projecting megakaryocyte- and erythroid cell-derived co-expression modules to longitudinal blood transcriptome samples from cohort 3 confirmed an association of early temporal changes of these features with fatal COVID-19 disease outcome. In sum, our longitudinal multi-omics study demonstrates distinct cellular and gene expression dynamics upon SARS-CoV-2 infection, which point to metabolic shifts of circulating immune cells, and reveals changes in megakaryocytes and increased erythropoiesis as important outcome indicators in severe COVID-19 patients. Coronavirus disease 2019 , caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is rapidly emerging into a pandemic resulting in more than 27 million cases (as of 10 th Sep, 2020) and a death toll of more than 900,000 people globally (https://coronavirus.jhu.edu/map.html). Since its emergence in Wuhan, China in December 2019 1,2 , it has spread globally by aerosol and droplet-mediated human-tohuman transmission [3] [4] [5] . COVID-19 shows a heterogeneous clinical course, ranging from asymptomatic carriers to severe cases with overwhelming inflammatory responses leading to organ failure and death. protective immune response via macrophages and monocytes that respond to the infection and foster an adaptive T and B cell reaction. Severe, and ultimately fatal, COVID-19 is associated with a dysfunctional immune response, characterized by systemic inflammation and widespread inflammatory lung affection. Critically ill COVID-19 patients show higher blood plasma levels of numerous cytokines and chemokines (often termed "cytokine storm"), e.g., granulocyte colony-stimulating factor (GM-CSF), tumour necrosis factor (TNF), IL-6, CC-chemokine ligand CCL2 and CXC-chemokine ligand 10 (CXCL10) 2,6-8 . Similar to other Betacoronaviruses, a profoundly impaired interferon (IFN) type I response with low interferon production and heterogeneous regulation of interferon-stimulated genes has been suggested to influence the course of severe COVID-19 9, 10 . Immunophenotyping studies have demonstrated several cellular hallmarks of the systemic inflammatory response to SARS-CoV-2 infection. A significant expansion of populations of IL-6 secreting CD14 hi CD16 hi monocytes as well as a decrease of non-classical (CD14 lo CD16 hi ) monocytes was shown in the peripheral blood of severe COVID-19 patients [10] [11] [12] [13] [14] . While a wide upregulation of inflammatory cytokine mRNA levels was not detectable in monocytic populations by singlecell RNA sequencing (scRNA-seq) 15 , another study demonstrated a broad impairment of the myeloid lineages 14 . Hyperinflammatory COVID-19 disease behaviour was associated with the appearance of proliferating, type I IFN activated CD14 + HLA lo suppressive monocytes and emergency granulopoiesis with elevated pre-neutrophil counts. Another common feature in many patients with severe COVID-19 is T cell lymphopenia, which is more pronounced in the CD8 + T cell compartment 2, [16] [17] [18] [19] . Several reports have highlighted the functionally exhausted phenotype of remaining T cells 7, 17, [20] [21] [22] . SARS-CoV-2 infection has been shown to elicit specific T cell and B cell responses, indicated by the appearance of SARS-CoV-2 peptidespecific T cells 23, 24 and the production of SARS-CoV-2 specific antibody responses 25, 26 , of which, however, the dynamics concerning disease outcome and lasting immunity are only incompletely understood. A significant disease burden is mounted by thrombotic complications associated with COVID- 19 . Thromboembolic events, including pulmonary embolism or thrombosis, are a frequent clinical feature of critically ill COVID-19 cases 12, 19 , sometimes despite sufficient anticoagulation. The diffuse alveolar damage in SARS-CoV-2 infection has been linked to the formation of vascular thrombi in the lungs 27 with alveolar capillary microthrombi nine times more prevalent in patients with COVID-19 than in influenza autopsies. Endothelial injury, endothelialitis and microthrombotic complications 28 also affect other organ systems, e.g. heart, liver, kidney and brain 29 . Patients exhibit elevated D-dimer levels, thrombocytopenia, complement activation, and thrombotic microvascular injury 30 . Predisposition to this severely heightened state of coagulation might be linked to direct endothelial damage, hypoxia, immobilization, diffuse intravascular coagulation, but also might be a consequence of the hyperinflammatory state per se. Several studies have suggested platelet hyperreactivity, pathological-platelet immune cell interactions 31 , and presence of megakaryocytes in affected lungs 32 as a determinant of severe COVID-19. However, a comprehensive view on the dynamics of thrombopoiesis and its association with disease course is missing. The clinically heterogeneous disease presentation renders individual molecular dynamics of the haematopoietic and immune cell compartments system in response to COVID-19 an important topic to understand the pivot points of the disease. As until now, omics-driven studies have used a cross-sectional, "single-layer" design to compare cellular and molecular states between mild and severe COVID-19, there is an urgent need for detailed insights into longitudinal trajectories of the disease in an integrated multi-omics approach and for comparing such high-density molecular data sets with detailed clinical characteristics of the individual patients. Two recent studies have demonstrated the power of longitudinal analysis using mostly flow cytometry-based methods 33, 34 . We hypothesized that a deep understanding of individual dynamics of functional genomic states of cellular compartments in the peripheral blood not only depicts the systemic response to SARS-CoV-2 but also may shed light on the importance of bone marrow precursor mobilization as a fundamental feature in critically ill COVID-19 patients. To elucidate cellular patterns and activated pathways of the systemic immune response to COVID-19, we applied a multi-omics approach using up to 5 longitudinal peripheral blood samples of 13 hospitalized patients and one additional recovery control from two University hospitals in Germany (Cologne and Kiel). To identify functional changes associated with moderate to severe disease trajectories in peripheral blood mononuclear cells (PBMCs) from these individual patients, we employed parallel single-cell RNA sequencing (scRNA-seq, 10x Genomics), single-cell BCR profiling, bulk mRNA sequencing (RNA-seq), BCR amplicon sequencing and multicolour flow cytometry. DNA methylation profiling by Illumina Bead Arrays (hereafter EPIC array) and multiplex cytokine ELISA analysis from serum was performed in a subset of seven patients (Figure 1a ). All patients were recruited at admission and samples were taken systematically at days 0, 2, 7, 10, 13 and/or at discharge. Three patients were diagnosed with Acute Respiratory Distress Syndrome (ARDS), two of which had a fatal disease course. Five patients received remdesivir after inclusion into this study. Patient demographics and clinical characteristics are described in Table 1 and individual detailed clinical data are reported in Supplementary Table 1. 14 age-and gender-matched healthy controls were processed in parallel. To describe the heterogenous disease trajectories over time, we used a modified WHO ordinal scale 35 , which also considers the behaviour of several inflammatory markers (serum CRP, serum IL-6 and ferritin, Table 2 ). The score was used to classify patients along their disease course (Figures 1b and 1c) enabling the interrogation of molecular states associated with transition between phases (e.g., complicated to early convalescent). Phases were defined as pseudotimes in accordance with WHO and the LEOSS register (www.leoss.net) to depict the longitudinal course of the disease: incremental (pseudotime 1, where clinical symptoms and inflammatory markers were increasing, ICU or non-ICU), critical (pseudotime 2, ICU, mechanically ventilated with signs of ARDS), complicated (pseudotime 3, state with severe signs of a systemic inflammatory response, ICU, high-flow oxygen, intubation readiness), moderate or early convalescent (pseudotime 4, supplemental oxygen, significant signs of systemic inflammation), late convalescent (pseudotime 5, intermittent supplemental oxygen, minor signs of inflammation), recovery/pre-discharge (pseudotime 6, no supplemental oxygen, absent inflammation markers) and long-term follow-up (pseudotime 7, at least two weeks after hospital discharge) ( Table 3 ). Note that pseudotimes 2 and 3 do not directly reflect the chronological order, but can also represent peak levels, i.e. a given patient might have gone from 1 to 3 without intubation/mechanical ventilation. We first analyzed scRNA-seq data from 358,930 cells with 10 Next, we quantified shifts in relative cell type proportions according to COVID-19 disease trajectories ( Figure 2f ). We observed a depletion of several cell types including NK cells and dendritic cells at the peak of disease severity similar to previous studies 14, 15 . Lymphopenia of both CD4 + and CD8 + T cells was present, but less pronounced in our data set during high disease activity. We also noted increased plasmablast proportions from the incremental phase to late convalescence, while B cells were depleted during early and late convalescence. Whilst the critical group (pseudotime 2) did not reach formal significance, possibly due to sample size, the data overall confirmed a strong and lasting activation of B cell immunity with an increase of circulating plasmablasts 13, 15 . Of note, we recognized the increased presence of several bone marrow-derived precursor cell types in the peripheral blood of COVID-19 patients. Prominently, megakaryocyte proportions were elevated throughout the course of the disease. To define potential cell populations, which might be directly infected by SARS-CoV2, we specifically interrogated ACE2 mRNA levels in the data set, which were below detection limit (<7 reads) in all cell populations (data not shown). Next, we were interested, whether changes in cell numbers correlated with clinical parameters. A correlation analysis of relative cell proportions with clinical activity parameters and a multiplex serum ELISA revealed that increased bone marrow precursor cells were associated with increased levels of IL-33, a T h 2 cytokine involved in regulating haematopoietic stem cell regeneration 38 and that elevated megakaryocytes were linked to heightened inflammatory parameters, including serum CRP, IL-6 (clinical routine and multiplex ELISA), IL-1β, IL-17 and IFN-α. Plasmablast proportions were correlated with serum levels of TNF-α, IL-10, CCL3, CXCL9 and IL-21, a factor critically involved in B cell differentiation to plasmablasts via STAT3 and BLIMP-1 (PRDM1) 39, 40 (Figure 2g ). To delineate the transcriptional response to SARS-CoV-2 infection at higher temporal resolution and to instruct further cell type selection from the single-cell data set, we next analysed whole-blood transcriptomic data of the 13 hospitalized patients from up to five timepoints along with the recovery control and compared the signatures against 14 healthy controls ( Figure 3a ). Principal component analysis showed a separation between healthy controls and COVID-19 patients on the first principal component (PC1) (Figure 3b ). Samples from COVID-19 patients taken at asymptomatic stages or after complete recovery (pseudotimes 6 and 7) also clustered with the healthy controls. Among the different samples from the same patient, critical and complicated timepoints (pseudotimes 2 and 3) tended to be located much further from the healthy controls than the milder and recovering timepoints on PC1 (Figure 3b ). We next performed pairwise differential expression analyses between controls and each of the disease trajectory pseudotimes. In total, 5,915 genes were differentially expressed between healthy controls and COVID-19 patients considering all different pseudotimes 14, 15 . Most of the upregulated transcripts were shared between two or more conditions. Neutrophil marker transcripts (DEFA3 and DEFA4) were particularly elevated in the timepoints with an active inflammatory response (pseudotime 2 to 4). Next, we employed ImpulseDE2 to construct a model to assess temporal changes in gene expression for individual disease trajectories 41, 42 . Note that this analysis follows a case-only design, exploits intra-individual variation over time and is thus complementary to the pairwise analysis. Since two of three patients reaching the critical category (pseudotime 2) were deceased soon after reaching this timepoint and did not experience a convalescent disease course, this category was excluded from this analysis and was only used to contrast involved in IL-1β (IRAK2, IL1RN, IL1B, ICAM1) and vasodilatory (AGTRAP, ADM, NTSR1, DM2, AOC1) signalling were highly expressed during the incremental trajectory (pseudotime 1). A broad downregulation of transcripts encoding ribosomal structural proteins was present from the incremental to the late convalescent state (pseudotimes 1,3, and 4), which might reflect a general suppression of the protein synthetic apparatus by type I interferons [43] [44] [45] . Opposingly, there was a strong upregulation of interferon signalling related transcripts (e.g., OAS1, OAS2, OAS3, IFI44L, STAT1) during the peak of disease activity, which was, however, suppressed in the critical disease category (Figure 3d and Supplementary Figure 2b) , confirming earlier reports 9, 10 . Transcripts involved in myeloid cell-mediated immunity and neutrophil degranulation were modestly upregulated during pseudotime 1, 3, and 4, but were strongly increased in the critical pseudotime 2. Notably, during late convalescence (pseudotimes 5 and 6) a strong signal of erythroid cell differentiation (haemoglobin and mitophagy related transcripts, e.g., HMGN, HBD, HBBP1, OPTN, FIS1) was detectable indicating a response to hypoxia 46 . To identify putative transcription factors (TF) responsible for the temporal change of gene expression we used the gene set resource DoRothEA to infer TF activity by enriched regulon analysis. The algorithm accounts for the activity and activity type of the TF downstream targets as well as alternative signalling pathways. Upregulated TFs in active disease were putatively related to inflammation and interferon signalling (IRF1, STAT3, ESR1, or SP1) as well as hypoxic conditions (HIF1A) (Supplementary Figure 2c) . Supporting the IL-21plasmablast axis identified in the first part of the single-cell analysis, PRDM1 (BLIMP-1) was predicted as significantly active both at the critical as well as at convalescent timepoints. Other TFs with a similar activity pattern are TEAD4, FOXO1, JUNB, SOX2, BACH2, GATA6, RUNX2, THAP11, SOX6, MAFK, and NFE2. A hypergeometric test on these TFs against the REACTOME database showed an enrichment of "cell differentiation pathway" (q-value = 0.03) and "factors involved in megakaryocyte development and platelet production" (q-value = 0.05). Next, we inferred the upstream network topology of gene expression changes using signed and directed protein-protein interactions 47 . We reconstructed a network for each pseudotime with a total of 203 unique nodes. To investigate the differences in network topology between pseudotimes, we calculated the degree centralities of every node states. The former are marked by MAPK14 (p38a) 48 , ESR1 49 and SMAD4, all regulators of stress and inflammation, while the central nodes of the latter are CREB1, MAPK9, FOXO1, GSK3B, which play a role in reducing inflammation 50, 51 and vascular remodelling 52 . In line with this, the number of inferred interactions decreased over time, which suggests substantial normalization of inflammatory signalling networks with recovery. We further constructed metabolic models of each pseudotime using the differentially expressed genes between different disease phases 53 and found that the inflammatory disease states are associated with higher numbers of predicted metabolically active pathways when compared to convalescence and healthy individuals (Supplementary Figure 2e) . To interrogate the potential presence of viral transcripts, we investigated the bulk RNA data set for presence of viral reads by a stringent mapping approach. We did not detect relevant amounts (>10) of viral reads in any sample. This finding was also confirmed by routine real time-PCR (E gene and S gene amplicon), which did not detect the presence of viral mRNA after 44 cycles in any sample (data not shown). To identify co-regulated modules of transcription regulated across the disease trajectory of COVID-19, we constructed gene-co-expression networks for all differentially expressed genes identified from the combination of pairwise and longitudinal analysis (6,317 genes) using weighted gene co-expression network analysis (WGCNA) 54 . Co-expression analysis builds on the hypothesis that genes with similar expression patterns are likely to have a functional relationship or are expressed in specific cell types present in the tissue of interest 55 . Gene co-expression analysis identified a total of 10 modules, which we refer to as M1-M10, of strongly co-expressed genes following distinct expression patterns throughout the Genes belonging to modules M1-M7 were upregulated in one or more disease pseudotimes, while those in modules M8-M10 had higher expression levels in the controls and recovery time point (Figure 4a and Supplementary Figure 2f) . Module M1, a general inflammationrelated module, which was broadly upregulated from pseudotime 1 to 5, is enriched with genes related to lymphocyte mediated immunity, immunoglobulin production and B cell mediated immunity, amongst others (Figures 4a, 4c and 4d ). M1 is also highly correlated with the proportion of plasmablasts detected from the scRNA-seq analysis (Figure 4b ) as well as D-dimers and CRP levels ( Figure 4c ). Notable biological processes enriched in module M2 were type I interferon response and proliferative activity (G2M transition) (Figure 4d ). Genes belonging to this module were upregulated in all active disease categories except the critical one ( Figure 3d ). M2 genes are also enriched in binding sites for transcription factors IRF1, STAT1, and STAT2 (Figure 4e ). Module M4 was associated with the presence of megakaryocytes in the peripheral blood as well as D-dimers and had two expression peaks, in the critical state (pseudotime 2) and in the early convalescent state (pseudotime 4), respectively. Module M7 contains transcripts related to heme and haemoglobin biosynthesis and coincided with TFBS motifs for GATA-1 and GATA-2, which are classical transcription factors related to erythroid cell differentiation and haematopoietic stem cells. This module, which is likely driven by hypoxic states, had higher levels in the critical phase (pseudotime 2) and was again upregulated in late convalescence (pseudotime 5), which negatively correlates with the prediction of the GATA-2 TF activity (Supplementary Figure 2c) . This biphasic pattern is likely related to hypoxia during highly acute inflammation (first peak) and weaning off supplemental oxygen during convalescence (second peak). Taken together, analysis of temporal gene expression patterns in whole blood of patients clearly depicts pathophysiological consequences of a SARS-CoV-2 virus infection along an idealized disease trajectory. Epigenetic changes have been shown to contribute to the pathophysiology of systemic inflammatory states 57 . We thus investigated DNA methylation (DNAm) patterns along the COVID-19 disease course following the workflow depicted in Figure 5a . We performed DNA methylation screening on whole-blood samples from a subset of the same patients (n = 6) ( Table 1 ) and compared them with a cohort of 6 healthy age and gender-matched controls. Bead arrays interrogating > 850,000 CpG sites across the entire genome covering 99% of RefSeq genes were employed for the analysis. The schematic analysis workflow is depicted in Figure 5a . A pairwise comparison with healthy controls identified between 46,071 and 69,733 differentially methylated CpG sites per pseudotime (Figures 5b and 5d) . A general preponderance of hypomethylated sites was present at each timepoint. Intersecting the differentially methylated positions (DMPs) between pseudotimes, we noted that most sites were unique to a respective category. Among the top 30,000 DMPs, 3804 DMPs were shared among the first three timepoints (pseudotimes 1, 2, and 3), which are clinically characterized by strong systemic inflammation. 875 DMPs were common between the last three pseudotimes, which reflect the convalescence trajectory with decreasing disease activity ( Figure 5c ). Of note, the analysis represents the sum signals of the DNA methylome in peripheral blood and thus many of the DMPs may actually reflect cell type-specific methylation patterns. A formal cellular deconvolution analysis using RnBeads 58, 59 identified that major parts of the COVID-19 associated DNAm signatures originated from granulocytes, B cells, NK cells and monocytes (Supplementary Figure 3a) . Next, we analyzed the enrichment of TF binding motifs within the regions containing differentially methylated CpG sites across timepoints using Locus Overlap Analysis (LOLA) 60 . In the inflammatory disease phase and again late in disease, we observed a significant overrepresentation of binding sites of the CCAAT Enhancer Binding Protein Beta (CEBPB) in hypomethylated regions ( Figure 5e ), which is a transcription factor present in activated monocytes 61 and in T and NK cells. CEPBP has a critical role for emergency granulopoiesis 62 . Interestingly, high levels of CEBPB activity have also been associated with B lymphocyte-to-granulocyte transdifferentiation, a process, which has been proposed in severe COVID-19 15 . Binding motifs for BATF, a cooperative transcription with heterologous interaction partners (e.g., BACH2 and IRFs) were strongly enriched at hypermethylated sites in the critical phase (pseudotime 2) and late during convalescence, indicating a potential antagonization of the function of this TF. The BATF family has several pleiotropic functions in adaptive immunity, e.g., regulating T h 17 or T h 2 immunity as well as promoting class switching in B cells [63] [64] [65] . In addition to the pairwise analysis, we also compared methylation patterns between subsequent pseudotimes in order to identify the changes in methylation occurring along the disease trajectory. While we did not observe significantly differentially methylated sites Subsequently, we integrated the DEG dataset with the observed DNA methylome changes to identify mRNA expression differences associated with cis-linked methylation changes. We hypothesized that this approach would reveal another layer of important genes as DMP-DEG pairs may represent a potentially longer-term modulation of cellular programs or differentiation events. We employed a hierarchical testing approach 66 As megakaryocytes and plasmablasts presented with unexpectedly large clusters of DMP-DEGs, we decided to focus on these cell types in greater depth. shown). Of note, as plasmablasts are notoriously sensitive to manipulation, we recognized that the freezing procedure for scRNA-seq slightly diminished the levels of intact plasmablasts compared to FACS data. Also, corresponding to flow cytometry data, we found similar expression patterns of marker genes for plasmablasts and/or plasma cells (CD27, CD38, MZB1, SLAMF7, SDC1 and HLA-DR), which hindered the distinction of the two cell types, prompting us to use the overarching term plasmablasts. Regardless, the longitudinal dynamics of increased plasmablast numbers were retained between the two methods. Projected in direct vicinity to conventional plasmablasts, we could distinguish a smaller cluster which expressed genes normally associated with neutrophils (e.g., ELANE, MPO and CAMP) (Figure 6e ) 15 . Unlike in the previous study, we also found such cells in healthy subjects, although at lower frequency (Supplementary Figure 4b) . Constructing a cell differentiation trajectory based on transcriptional reconfiguration of B cells using monocle3 72 , we highlighted the progression of transitional B cells into naïve and memory B cells, with a separate memory B cell cluster being most likely CD45RBcells 73 (Figure 6f ). In parallel, we could retrace the progression of plasmablasts, which did not cluster based on immunoglobulin classes but rather based on pseudotimes with cells from hyperinflammatory phases present further away from the root of the cell trajectory ( Supplementary Figures 4a and 4b) . Interestingly, cells previously identified as neutrophil-like cells associated to the plasmablast compartment were not continuous within the plasmablast differentiation ( Figure 6f ). We next turned to the analysis of BCR repertoire in the different B cell compartments using heavy-chain bulk-and scBCR-seq ( Supplementary Figures 4d-o) . In the bulk data set, we identified all together 596,882 unique BCR CDR3 heavy-chain sequences, while for scBCRseq we had information referring to 14,785 cells. Diversity analysis showed a heightened clonality, which sharply increased at early timepoints and then gradually decreased in the As we hypothesized that plasmablasts are important immunological players during SARS-CoV-2 infection, we next analysed the longitudinal gene expression patterns of the 6,295 plasmablasts along the disease trajectory. Indeed, significant changes pointed to a shift of pathways and cellular programs across timepoints ( Figure 6g ). Whereas in circulating plasmablasts from healthy controls, transcripts related to early immunoglobulin production (IGHA2), BCR signalling (CD79A) and MHC-II maturation prevailed, the incremental inflammatory phase of COVID-19 patients was characterized by ER stress/protein folding (XBP1) and cell proliferation (PIM2, S100A4 and NARF). Type I IFN response genes (IFI27, IFI6, IFITM1) were present in the plasmablasts along the trajectory until late in the disease (up to pseudotime 5), yet such genes were absent from plasmablasts in critically ill patients (pseudotime 2). The convalescence and recovery states (pseudotimes 5, 6 and 7) were characterized by upregulation of HLA class II (HLA-DQA2 and HLA-DRB5) and upregulation of CD52, which is known to be expressed on specific activated B cells (ABCs), that are committed to the memory B cell lineage 74 . Throughout disease we also identified an upregulation of SLC1A4, a neutral amino acid transporter and a potential upstream regulator of metabolic changes (Figure 6i ). IL-16 secretion, which has been shown to support migration of CD4 + T cells 75 Systemic inflammatory responses are known to consume platelets, which exert broad immune and inflammatory functions in addition to their well-established haemostatic role 78, 79 . The interaction of platelets with neutrophils orchestrates the formation of neutrophil extracellular traps 79, 80 , which elicits a rapid depletion of platelets from the circulation, resulting in a transient thrombocytopenia 81, 82 . Interestingly, platelet-rich thrombi and increased megakaryocytes were found in the lungs of deceased patients 28 and pulmonary and cerebral embolism is an important contributor to morbidity and mortality in COVID-19 83 . Transiently downregulated transcripts comprised of ODC1 (ornithine decarboxylase), the rate-limiting enzyme for polyamine synthesis 84 , which is known to inhibit platelet aggregation 85 , and TGFB1 ( Figure 7f ). Of note, low levels of TGFB1 in megakaryocytes are involved promoting a regenerative state of HSCs in the bone marrow 86 . TREML1 and ITGA2B (CD41) expression as canonical marker transcripts for megakaryocytes and platelets 87 remained rather stable throughout the disease course with a slight upregulation in the critical phase. IFITM3, IFI27, and IFITM2, which were shown to be induced in emergency megakaryopoiesis, were upregulated in the inflammatory pseudotimes 1, 2, 3, and 4, indicating a lasting interferon response throughout the disease trajectory in megakaryocytes. Furthermore, we validated our findings in an independent cohort of mild and severe COVID-19 14 , which confirmed not only higher numbers of megakaryocytes in severe patients ( Figure 7h ), but also confirmed the upregulation of IFITM3, PKM, ITGA2B (CD41), and IFITM2, and the downregulation of ODC1 and TGFB1 in the severely ill patients (Figure 7f ). We next employed our metabolic modelling approach to depict active metabolic pathways in megakaryocytes. They showed increased metabolic activity along the disease trajectory compared to healthy patients, albeit at a lower level compared to plasmablasts ( Figure 7i ). Notable predicted processes were related to energy metabolism (pyruvate metabolism, glycolysis, and ROS detoxification). Metabolic plasticity related to these processes, but also a direct function of pyruvate kinase M in PI3K/Akt signalling has been shown to enhance platelet aggregation 88 Table 3 ). We first sought to correlate the levels of previously defined co-expression modules (see In a reverse approach, we next asked which transcripts displayed longitudinally different expression patterns between the two timepoints in survivors vs. non-survivors. We found that while in survivors only 3 transcripts were regulated, 182 transcripts were significantly different between the first and the second time point (Figure 8c ). Of these transcripts, 130 were contained in the previously defined temporal co-expression modules from cohort 1 with a significant enrichment of transcripts related to M2, M4, and M7. To investigate cell-type specific expression patterns of these fatality-associated transcripts, we plotted their respective average expression values for each identified cell population from the inflammatory states from cohort 1. We observed distinct clusters of genes which had high expression levels in specific cell types. While the expression signature for M2 genes marked a broad array of cell types, such as monocytes, granulocytes, NK cells, proliferative lymphocytes and CD8 + T cells, M3 and M4 genes were mostly specific for monocytes, with few highly expressed transcripts attributed to megakaryocytes. A large proportion of M7 genes painted the erythroid lineage, a separate cluster was expressed specifically in megakaryocytes, e.g., PBX1, GMPR, ARHGEF12, TRIM58, and PDZK1IP1 (Figure 8d ). Similar to the transcriptional patterns, predicted TF activities of the two cohorts were highly correlated for the inflammatory disease states (Permutation test, p-value < 10 -16 ). Lastly, we quantified the differential regulation of transcription factors over time in survivors vs. nonsurvivors via a moderated t-test using limma 91 slower convalescence), we ordered patient samples according to a longitudinal "pseudotime", which takes into account the WHO ordinal scale and inflammatory markers. In the cohort 1, we used an array of temporal comparison techniques (pairwise analyses between healthy and respective disease pseudotimes, longitudinal comparisons along with the categories and impulse models) and cross-validated scRNA-seq-derived signatures and bulk RNA and DNA methylation data. This longitudinal analysis provides a clear chronological rank order to some of the changes observed in prior studies: we observe a transient increase of plasmablasts and a relative decrease of memory and naïve B cells in the scRNA-seq data as well as the flow cytometry data from peripheral blood, which coincides with inflammatory severity and normalizes with convalescence. The expression of CD138 on a large fraction of plasma cells during the disease supports the theory that these cells are activated after being non-specifically mobilized from the bone marrow or other tissues. In contrast to a previous smaller study 15 , we present evidence that plasmablasts with neutrophil-like properties are present in healthy individuals, yet in COVID-19, particularly during the critical and complicated pseudotimes, this cell population increases and contributes to the metabolic hyperactivity signal. We saw two distinct co-expression modules indicating the increased presence of plasmablasts also in the bulk data, which positively correlate with several inflammatory markers (CRP, IL-6). While the first PB module (M1) is characterized by broad GO terms relating to lymphocyte activation and cell proliferation, the second module (M2) specifically shows a compromised type I IFN signature at the peak of the disease. Downregulation of this module over time was significantly associated with a fatal outcome in cohort 3. Several interferon-related genes (IFI6, IFI27) follow a similar pattern in plasmablasts in the scRNA-seq data from cohort 1 and 2, corroborating the suppression of IFN signalling by severe SARS-CoV-2 infection in plasmablasts themselves. Of note, we found that the COVID-19 plasmablasts were predicted to be highly metabolically active in a systems biology modelling approach 77 , beyond their expected upregulation of an unfolded protein response 92 . Among the pathways from the transcriptional pattern-derived model, we identified glycolysis and amino acid catabolism to be transiently activated, while NAD + energy metabolism, vitamin B2 and several transport processes were specifically inhibited at the critical peak of the disease in plasmablasts, when compared to other B cell subpopulations. The changes argue for the role of plasmablasts as a nutrient sink, which was already observed in extrafollicular plasmablasts as a hallmark of a systemic inflammatory response in severe malaria 76 . Metabolic hyperactivity of plasmablasts in that study led to nutrient deprivation of the germinal center reaction, limiting the generation of memory B cell and long-lived plasma cell responses. The predicted lower energy availability at the peak of COVID-19 could indicate excessive shuttling of glucose into antibody glycosylation, which might ultimately contribute to metabolic exhaustion of the cells [93] [94] [95] and/or altered glycosylation patterns of antibodies, which were linked to severe COVID-19 96, 97 . We also found several other temporal signatures in hospitalized COVID-19 patients from the scRNA-seq data set (cohort 1), which correspond to SARS-CoV-2-induced changes observed in cross-sectional studies: we see an early and lasting depletion of NK cells and a sustained increase of the monocytic compartment, which was present until the late follow-up time point 14, 15 . We observed a lasting lymphopenia of both the CD4 + and CD8 + T cell compartment, which however was less prominently linked to the hyperinflammatory phase compared to other studies. Interestingly, we found in our DNA methylation data that hypomethylated positions were highly enriched in cis of canonically upregulated transcripts, which were related to positive regulation of TNF secretion, IL-1β release and innate immune signalling. Vice versa, downregulated transcripts comprised T cell receptor signalling and negative regulation of ATP metabolism, indicating a potential long-term regulation of the immunological misfiring 33,98 by epigenetic processes. Together these changes clearly suggest effects of COVID-19 immunopathology beyond the immediate cytokine release syndrome. Most strikingly, our longitudinal approach identified two other cellular features induced by COVID-19, which were unrecognized in previous studies and are related to non-immune cell populations. First, we found a significant increase of megakaryocytes, which carried a molecular signature of a strong type I IFN response. These cells were present throughout the disease course and were associated with two longitudinal co-expression modules from the bulk RNA sequencing data (M3 and M4). Both modules were positively correlated with serum levels of D-dimers, suggesting a link between the observed megakaryocyte signature and the inflammation-induced pro-coagulative state, which has been observed as a potentially fatal complication in COVID-19 patients. Interestingly, one of the top upregulated transcripts in megakaryocytes was IFITM3, which encodes a protein known to confer antiviral activity in megakaryocytes and platelets 99 . Metabolic modelling suggests that in the hyperinflammatory states, a shift towards higher rates of pyruvate metabolism and glycolysis occurs, which has been shown to sensitize platelets towards activation and aggregation 100 . Another interesting observation was the persistent downregulation of the TGFB1 transcript along the disease axis. Whereas TGFB1 in platelets has been commonly associated with a pro-fibrotic function, e.g., in hypertensive cardiac remodelling 101 , its expression in megakaryocytes orchestrates homeostatic quiescence and promotes the stress-induced expansion of haematopoietic stem cells 86 . The observed increase of circulating HSCs and other precursor cells including megakaryocyte-erythroid progenitors (MEPs) argue for a significant influence of COVID-19 on the megakaryocytic lineage, which does not only represent a bystander response to increased platelet consumption but also contributes to viral defence and may alter aggregative properties of platelets 31 . Although thrombopenia has been observed as a clinical correlate of critical COVID-19 (metanalysis in 102 ) , it is unlikely that direct infection of megakaryocytes as seen in Dengue fever is responsible for this alteration. We found no evidence of neither ACE2 expression in megakaryocytes nor any virus-associated reads in the cell population (data not shown). Yet, the continuous presence of type I IFN signals, as seen in our data set, has been shown to be sufficient for the exhaustion of emergency thrombopoiesis, an increase of the aggregation potential of platelets and to contribute to the vicious circle of platelet activation and wide-spread thrombus formation, e.g. in neutrophilderived NETs 103,104 . The second cellular feature was primarily observed in the bulk RNA-seq data and was related to the co-expression module M7. We saw a biphasic up-regulation of a transcript group that comprises canonical components of erythropoiesis, which are most likely related to the presence of reticulocytes. GATA-1 transcription factor binding motifs linked to hypoxiainduced stress erythropoiesis 105 were significantly enriched in the module. We thus reasoned that this feature reflects a canonical response to hypoxia as it is present in critically ill patients and at a later stage when patients are weaned of supplemental oxygen. Post-hypoxia polycythaemia and the presence of different erythroid progenitors in the circulation has been studied as a response mechanism of the bone marrow to acute hypoxic insults and critical illness since decades 106 14 patients from two independent University hospitals (Cologne, Kiel) were recruited for the longitudinal multi-Omics study. Eligibility criteria included age For validation of cellular findings from our prospective cohorts, data from two independent cohorts were analysed: The scRNA-seq data from 18 patients admitted to the University Hospital Bonn 14 To assess disease severity based on oxygen need and ventilation state, but also to include the inflammatory markers CRP, IL-6 and ferritin as a measure for systemic inflammation, a clinical compound scoring system was defined in accordance to the WHO Ordinal Scale and a scoring system for CRP, IL-6 and ferritin derived from observations in the LEOSS registry (see Table 2 ). The sum of the scores of each subcategory is used as the clinical score of the patients of each day. Based on the clinical score, disease severity phases were defined. In brief, each increase in the clinical score results in the disease phase "incremental", while the other phases depend on the absolute clinical score (see Table 3 ). In case the clinical score is 9, the disease phase is set to "critical", if the WHO Ordinal scale score is 6 or higher. Serum cytokines were analysed using a "Human Magnetic Luminex assay" (Biotechne, Minneapolis, Minnesota, US) with 22 analytes: APRIL, BAFF, CCL2, CCL3, CD40L, CD138, CXCL9, CXCL10, IL-1β, IL-2, IL-4 IL-6, IL-10, IL-12, IL-13, IL-17, IL-18, IL-21, IL-33, IFN-α Blood (2.7 mL) was taken from each patient into an Ethylenediaminetetraacetic acid (EDTA) monovette (Sarstedt) to decelerate blood coagulation. The monovette was centrifuged for 15 min at 3000 rpm and the buffy coat was frozen in micronic tubes at -80°C. DNA was An in-house RNA-seq pipeline was used to map and align the sequenced data (https://github.com/nf-core/rnaseq). Adapters and low-quality bases from the RNA-seq reads were removed using Trim Galore (version 0.4.4), which is a wrapper tool for Cutadapt and FastQC. Reads that were shorter than 35 bp after trimming were discarded. The filtered reads were mapped to the human genome (GRCh38, gencode version 25) using STAR aligner (version 2.5.2b) 109 . featureCounts (version 1.5.2) was used to estimate the expression counts of the genes. The expression counts were normalized across samples using the DESeq normalization method. Differentially expressed genes between healthy controls and each of the COVID pseudotime samples were identified using the Bioconductor package DESeq2 (version 1.20.0). Genes with FDR adjusted p-value of less than 0.05, log fold change greater than 0.5 or less than -0.5 and average expression counts of more than 100 were regarded as differentially expressed (DEGs). Longitudinal differential expression analysis of the COVID samples was performed by applying the case-only analysis from the Bioconductor package ImpulseDE2 (version 1.4.0). Pseudotimes 1, 3, 4, 5, and 6 were used as single timepoints of a timecourse experiment and the patient IDs were regarded as batch effects in order to perform a paired analysis. To identify the transcripts regulated longitudinally in survivors and nonsurvivors from the Nijmegen cohort, differentially expressed genes between in the two selected time points were identified using DESeq2 for survivors and non-survivors separately. To perform a paired analysis, patient ID was used as batch effect. Modules of co-expressed genes were identified using the WGCNA package for R (version 1.69). All differentially expressed genes identified from the pairwise and longitudinal analysis Bulk BCR libraries were prepared starting from 100 ng of total RNA isolated from PAXGene tubes. Library construction protocol was performed as previously described 110 To quantify the amount of virus present in the blood of COVID-19 patients, reads from whole blood RNA-seq data were first aligned to the human reference genome (GRCh38) using STAR with default parameters. The reads that did not map to the human genome were then aligned to the SARS-CoV-2 reference genome (NC_045512.2) using STAR with slightly between healthy controls and each of the COVID-19 pseudotime samples as well as between sequential COVID-19 pseudotime samples were identified using the automatically selected rank cutoff of RnBeads. Gene set enrichment analysis (GSEA) was conducted for the co-expression modules using GSEA desktop application. Pre-ranked analyses against Hallmark, KEGG and GO (Biological Processes) genes sets were conducted for each of the modules by ranking all genes by the module membership score. FDR of 0.05 was used as the significance threshold. All gene ontology enrichment analyses were conducted using the Bioconductor package topGO (version 2.32.0), with all expressed genes as the universe set. In the topGO analysis, the Fisher.elim p-value, calculated using the weight algorithm, of 0.05 was used as the significance threshold. Transcription factor binding sites (TFBS) enriched in the promoter regions of the coexpression module genes were identified by conducting enrichment analysis using the Bioconductor package LOLA (version 1.14.0). Promoter regions were defined as the region between 1,500 bp upstream to 500 bp downstream of the transcription start site. Predicted transcription factor binding sites (TFBS) enriched in DMPs were identified by conducting enrichment analysis using the Bioconductor package LOLA (version 1.14.0). For the integrated analysis of gene expression with DNA methylation, we first identified DMPs located 5,000 bp upstream and downstream of the transcription start sites of DEGs. Spearman's rank correlation coefficient between the normalized expression count of each DEG and the methylation intensity (β-values) of its corresponding DMPs were calculated. To test the statistical significance of the correlations, we calculated the false discovery rate (FDR) using a permutation approach. Blood (2 × 8 mL) was collected using venipuncture technique and processed within maximum 30 minutes. PBMCs were isolated using the BD vacutainer® cell preparation tube Single-cell libraries were generated using the Chromium Next GEM Single Raw feature-barcode matrixes were filtered using Seurat package (version 3.1.5) in R environment 113, 114 ; low quality cells that were potentially disrupted or doublets cells were removed from the analysis using number of features (number of reads mapping to gene between [200;5000]) or percentage of mitochondria (lower than 25%). Each filtered sample matrix was then merged into a single object containing 358,930 cells with overall reads mapping to 22,519 human genes. The merge object was normalized and scaled using LogNormalized() and ScaleData() functions respectively. Principal component analysis was performed utilizing the top 2,000 variable genes. We identified the clusters using the standard k-nearest neighbour method based on 80 dimensions with a 0.2 resolution. In total 37 clusters were displayed as a Uniform Manifold Approximation and Projection (UMAP). Cluster cell types were identified by their corresponding gene signatures using the Wilcoxon rank sum, with a cut-off based on genes expressed in more than 25% of the cluster cells and BCR information was merged with scRNA-seq expression, thus, we were able to discern IG class information per cell type and displayed it in the form of a UMAP or monocle3 cell trajectory. Blood metabolites originating from the Human Metabolome Database (HMDB) 117 ; specifically, an advanced search of blood metabolites from healthy adults was initially conducted in March 2019. In the same time period, a list of all metabolites in Recon 3D 118 was downloaded from Virtual Metabolic Human (VMH) database 119 . The latter contains the HMDB indices of the compounds, which enabled the merging of the two databases into one (Spring 2020). Compounds were removed from the database (e.g., drug-related ones or without FooDB IDs (https://foodb.ca/)) and the metabolites nomenclature was altered to be compatible with an adapted version of the model Recon 2.2 120 . All values were transformed to mM to correspond with mean values of the HMDB database (cut-off of values > 10 -6 ). Water was set to 55,000 mM, and pH was set to 7.4. All calculations were conducted with the R packages sybil (version 2.1.5) 121 and sybilSBML (version 3.0.5) 121 along with their dependencies. For the reconstruction of metabolic models from bulk sequencing data we used a previously described two-step approach that first discretizes gene expression based on differential gene expression analysis and subsequently reconstructs metabolic models based on gene expression states 53, 122 . Differentially expressed genes between healthy controls and each of the COVID pseudotimes from previous differential expression analysis were used separately to build generalized linear models and tested with disease state as an independent variable. Wherever possible, i.e. when models reached full rank, we included the donor identifier to control for paired samples with similar genetic background in the data. The significance cutoff used for optimizing independent filtering was adjusted to α = 0.05 before differentially expressed genes were extracted from the tests. For each gene, based on the directionality of changes in gene expression activity between conditions and the significance of changes, we determined a binary activity (on or off) if a gene had at least one case of significant change in activity (adjusted p-value < 0.05) between any pair of conditions. Subsequently, we used the binary gene activity as an input into the iMAT approach 123 on a generic metabolic model of humans (Recon 2.2) 120 constrained with the serum metabolic environment. In order to test method-inherent uncertainties in the reconstructed contextspecific metabolic network, the model reconstruction procedure was repeated fifty times while leaving out gene activity data for 5% of the genes each time. Reconstructions of cell-specific metabolic models were created by integrating single-cell transcriptomics with a human genome-scale metabolic network 120 conditioned with the serum metabolic environment. We employed a two-step approach, in which StanDep 77 first identifies a core reaction list across cell types. Second, the FASTCORE algorithm 124 Tissue-and cell-specific models were stratified by cell/tissue type (megakaryocytes, plasmablasts, memory B cells, naïve B cells and NK cells) and annotated with clinical metadata (COVID-19 disease status) according to donor and sampling timepoints. Reactions per pathway and cell were counted for a total of 82 metabolic pathways that were identified in the models. For each of the four model types, pathways were filtered out if reaction counts were zero across all models of that type. Differential pathway activity was determined for each pathway by comparing reaction counts across all eight pseudotimes via Kruskal-Wallis test as implemented in the R-package coin (parameters: two-sided test, unpaired, averagescores for ties, and without continuity correction). Resulting probability values were corrected for multiple testing via the Benjamini and Hochberg method. Significantly differential active pathways across disease states were determined via this method for all four model types (total PBMC, B cells, megakaryocytes, and plasmablasts) separately with an FDR cut-off of ≤ 0.05. For the heatmap representation, pathways that were identified as significantly differential active in at least two of the four model types were selected and ordered by pvalues of the total PBMC models. Putative transcription factor activity from RNA-seq data was assessed per pseudotime against healthy controls using the human gene set resource DoRothEA v1, which provides a curated collection of transcription factor and target genes interactions (the regulon) from different sources 127 . Only interactions with high, likely, and medium confidence (levels A, B, C) were considered. Regulons were statistically evaluated using the R package viper Table 1 and Supplementary Table 1. Figure 1 C6orf25 SPARC GP9 GNG11 MYL9 SDPR HIST1H2AC PF4 TUBB1 PPBP SMIM24 CYTL1 CD34 EGFL7 KIAA0125 RP11-620J15.3 CDK6 SPINK2 SOX4 PRSS57 MZB1 IGHV6-1 IGLV3-1 IGKV4-1 IGHG1 IGHA1 IGKC IGLV3-25 JCHAIN IGKV3-20 RALGPS2 HLA-DPA1 LINC00926 BANK1 CD79B HLA-DRA HLA-DQA1 CD74 MS4A1 CD79A APP CCDC50 TCF4 SERPINF1 LILRA4 IRF8 IRF7 ITM2C PLD4 KLRG1 IL32 GZMA CD8B GZMK GZMH CD8A CCL5 CD3E RPS12 NOSIP LDHB LEF1 CCR7 TCF7 MAL IL7R LTB MKI67 HMGN2 H2AFZ HMGB2 HIST1H4C RRM2 TUBB TYMS TUBA1B STMN1 CLIC3 CTSW CST7 FGFBP2 NKG7 PRF1 PTGDS GZMB SPON2 GNLY SNCA AHSP HBM CA1 SLC25A37 HBD ALAS2 HBA1 HBA2 HBB HIST1H1E SYNE2 MACF1 RNF213 NKTR UTRN MTRNR2L12 DDX17 RSRP1 MALAT1 CD14 VCAN SERPINA1 AIF1 CST3 FCN1 S100A12 LYZ S100A9 S100A8 CD4 + T cells OAS2 LY6E RSAD2 OAS3 IFI44L HIST1H2BF STAT1 BRCA1 HIST1H2AG HIST1H2BN HIST1H2AE HIST1H3H EPSTI1 HIST1H2BH HIST1H2BO DNAJC1 CDC6 RNASE3 ORM1 CTSG ALCAM VNN1 IDH1 LY6G6C PPARG MAPK14 ACSL1 GM2A LILRA6 BST1 TLR5 HEXB NAIP ITGA7 IL10 MARCO CXCR2 C1R C5AR1 TNFSF14 ECE1 MYD88 AKIRIN2 TLR2 TIMP2 IFNGR2 RARA SPI1 PRKCD SERPINA1 FPR1 NLRP12 GDF15 OPRL1 IRAK2 CCR1 ITFG1 AOC1 HPN LILRB4 GPR17 AGTRAP IL1RN INSL3 ADM IL1B NTSR1 ICAM1 IGHV1-2 ITGB1 RPS15A HLA-DRB5 EEF1A1 TRBC2 IL16 S100A6 CD52 RPS27 RPL41 HLA-DQA2 RPL26 IGHM LYZ RPS29 RPS4Y1 IGLV3-1 IGHG3 IGLC3 IGHG1 IFITM1 IGHG4 XIST IFI6 IGLV3-25 S100A8 S100A9 IGHV3-30 IGLV1-40 MTRNR2L8 IGKV4-1 IGHV3-23 LAPTM5 MT-ND4 GSTP1 PRDX1 CTSH IFI27 S100A4 NARF SRSF7 IGHV6-1 IGHG2 PIM2 IGKV1-12 XBP1 IGKV3-20 PEBP1 LIMD2 MT-ATP8 CD74 VIM CD79A IGHA2 MT-CO2 RPL3 MTRNR2L12 DDX60 TRIM22 GBP1 OAS2 STAT1 GCH1 APOL6 EPSTI1 OAS3 IFI44L RSAD2 MX1 OAS1 FCGR1A IFI27 ZBP1 TIFA SAMD9L CD274 IFIH1 PRKDC FLT3 PANX2 PIK3AP1 TSC22D3 ZNF608 IL1B DOCK4 TPST1 PER1 IRS2 LACTB RCN3 TSPO ADAMTS2 DAAM2 SAP30 CR1 YWHAH DBN1 FURIN CAMP MMP8 ABCA13 PTX3 BPI PRTN3 TCN1 OLR1 LCN2 ERG LTF NBN PDE4B TNFAIP6 FHDC1 DAPP1 GFI1 GSPT1 RGCC TSPAN5 BPGM FBXO7 GLRX5 SPTB MARCH8 SLC14A1 RUNDC3A CA1 KLC3 SELENBP1 AHSP SLC4A1 EPB42 MYL4 SLC25A39 FECH RAP1GAP TNS1 HEMGN NFIX KLF1 FAM46C KANK2 IGF2BP2 YBX3 RPIA ASCC2 SLC2A1 RBM38 TRAK2 UBXN6 SIAH2 DNAJB2 TRIM58 PDZK1IP1 TMCC2 ANK1 BCL2L1 DMTN MKRN1 FKBP8 ARHGEF12 GMPR PBX1 RANBP10 SRRD NEDD4L ALDH5A1 SHARPIN RNF187 CNPPD1 TEX2 AZU1 ELANE MYL9 AP001189.4 SPARC DEFA3 GAS2L1 PTGDR2 LTB PARP14 IFIT1 IFIT3 SPN ZBTB16 DDX58 XAF1 RTP4 ISG15 ETV7 LRRC8A IFITM1 GBP5 RNF167 CIZ1 HERC5 CNOT3 AP2A1 IFIT2 IFI44 ZFHX3 TNFSF13B ADGRE1 DOC2B DPYSL2 IFI6 INHBA S100A10 PLEKHG1 TCF3 PTMS RP11 20D14.6 TGM2 LSM6 RAD23A EPB41 TMEM63B NPRL3 CMPK2 FTH1 SH3BGRL3 RP11 678G14.3 NAP1L1 HSPB1 Figure 8 A Novel Coronavirus from Patients with Pneumonia in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals Droplets and Aerosols in the Transmission of SARS-CoV-2 Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 Clinical and immunological features of severe and moderate coronavirus disease 2019 Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure A Dynamic Immune Response Shapes COVID-19 Progression Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embolism? COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome Suppressive myeloid cells are a hallmark of severe COVID-19. medRxiv A single-cell atlas of the peripheral immune response in patients with severe COVID-19 Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Clinical Characteristics of Coronavirus Disease 2019 in China Eosinophilic colitis in a boy with a novel XIAP mutation: a case report Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis Functional exhaustion of antiviral lymphocytes in COVID-19 patients Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19) Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals Antibody responses to SARS-CoV-2 in patients with COVID-19 Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center Megakaryocytes and platelet-fibrin thrombi characterize multiorgan thrombosis at autopsy in COVID-19: A case series Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description Thrombotic microvascular injury is not mediated by thrombotic microangiopathy despite systemic complement activation in Covid-19 patients Platelet Gene Expression and Function in COVID-19 Patients Illuminating COVID-19 lung disease through autopsy studies Longitudinal analyses reveal immunological misfiring in severe COVID-19 Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage Massively parallel digital transcriptional profiling of single cells IL-33-Induced Hematopoietic Stem and Progenitor Cell Mobilization Depends upon CCR2 IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6 ImpulseDE: detection of differentially expressed genes in time series data using impulse models Impulse model-based differential expression analysis of time course sequencing data Suppression of human ribosomal protein L23A expression during cell growth inhibition by interferon-beta Ribosomal protein mRNAs are primary targets of regulation in RNase-L-induced senescence Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC) The pathways of mitophagy for quality control and clearance of mitochondria From expression footprints to causal pathways: contextualizing large signaling networks with CARNIVAL Role of p38-mitogen-activated protein kinase in COPD: pathobiological implications and therapeutic perspectives Estrogen receptors regulate innate immune cells and signaling pathways GSK3: A Kinase Balancing Promotion and Resolution of Inflammation The role of the transcription factor CREB in immune function JNK2 regulates vascular remodeling in pulmonary hypertension A Genome-Scale Database and Reconstruction of Caenorhabditis elegans Metabolism WGCNA: an R package for weighted correlation network analysis Coexpression analysis of human genes across many microarray data sets InnateDB: systems biology of innate immunity and beyond--recent updates and continuing curation Inflammatory cytokines and organ dysfunction associate with the aberrant DNA methylome of monocytes in sepsis Comprehensive analysis of DNA methylation data with RnBeads RnBeads 2.0: comprehensive analysis of DNA methylation data LOLA: enrichment analysis for genomic region sets and regulatory elements in R and Bioconductor Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity C/EBPβ is required for'emergency'granulopoiesis Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks The transcription factor BATF controls the global regulators of classswitch recombination in both B cells and T cells The AP-1 transcription factor Batf controls T(H)17 differentiation Exposure to the gut microbiota drives distinct methylome and transcriptome changes in intestinal epithelial cells during postnatal development A functional methylome map of ulcerative colitis Epigenetics and Trained Immunity Antibody responses to viral infections: a structural perspective across three different enveloped viruses Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing Single-cell mRNA quantification and differential analysis with Census An Integrated Multi-omic Single-Cell Atlas of Human B Cell Identity Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination B lymphocyte-derived IL-16 attracts dendritic cells and Th cells Infection-induced plasmablasts are a nutrient sink that impairs humoral immunity to malaria Capturing transcriptomic variability improves contextspecific metabolic models Platelets and the immune continuum Platelets: at the nexus of antimicrobial defence Platelets: bridging hemostasis, inflammation, and immunity Effects of endotoxemia on thrombopoiesis in men Role of TNFR1 and TNFR2 in TNF-induced platelet consumption in mice Incidence and mortality of pulmonary embolism in COVID-19: a systematic review and metaanalysis Human ornithine decarboxylase paralogue (ODCp) is an antizyme inhibitor but not an arginine decarboxylase Inhibition of platelet aggregation by putrescine, spermidine, and spermine in hypercholesterolemic rabbits Megakaryocytes maintain homeostatic quiescence and promote postinjury regeneration of hematopoietic stem cells A TREM family member, TLT-1, is found exclusively in the alpha-granules of megakaryocytes and platelets Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins Manipulating Metabolic Plasticity By Targeting Pyruvate Kinase M2 in Platelets Inhibits Arterial Thrombosis Methylglyoxal and glucose metabolism: a historical perspective and future avenues for research limma powers differential expression analyses for RNAsequencing and microarray studies Ufbp1 promotes plasma cell development and ER expansion by modulating distinct branches of UPR Long-Lived Plasma Cells Have a Sweet Tooth Mitochondrial Pyruvate Import Promotes Long-Term Survival of Antibody-Secreting Plasma Cells Metabolic Links between Plasma Cell Survival, Secretion, and Stress Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19 Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19 Human megakaryocytes possess intrinsic antiviral immunity through regulated induction of IFITM3 Targeting Metabolic Enzyme Pyruvate Kinase M2: A Novel Strategy to Inhibit Platelet Function and Arterial Thrombosis Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome Vascular occlusion by neutrophil extracellular traps in COVID-19 Hypoxia-inducible factor 1-mediated human GATA1 induction promotes erythroid differentiation under hypoxic conditions Kinetics of erythroid and myeloid stem cells in post-hypoxia polycythaemia The kinetics of hematopoietic stem cells during and after hypoxia Intermittent hypoxia mobilizes hematopoietic progenitors and augments cellular and humoral elements of innate immunity in adult men STAR: ultrafast universal RNA-seq aligner Analysis of the B cell receptor repertoire in six immune-mediated diseases MiXCR: software for comprehensive adaptive immunity profiling Identification of common molecular subsequences Integrating single-cell transcriptomic data across different conditions, technologies, and species Comprehensive Integration of Single-Cell Data MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data Improved scoring of functional groups from gene expression data by decorrelating GO graph structure HMDB 4.0: the human metabolome database for 2018 Recon3D enables a three-dimensional view of gene variation in human metabolism The Virtual Metabolic Human database: integrating human and gut microbiome metabolism with nutrition and disease Recon 2.2: from reconstruction to model of human metabolism Sybil--efficient constraint-based modelling in R The Inducible Response of the Nematode Caenorhabditis elegans to Members of Its Natural Microbiota Across Development and Adult Life iMAT: an integrative metabolic analysis tool The FASTCORE Family: For the Fast Reconstruction of Compact Context-Specific Metabolic Networks Models Creation and analysis of biochemical constraint-based models using the COBRA Toolbox v.3.0 Benchmark and integration of resources for the estimation of human transcription factor activities Functional characterization of somatic mutations in cancer using network-based inference of protein activity We Figure 5 Tables Moderate/early convalescence 4 -5 6Late convalescence 3 7Long-term follow-up 1 -2 * If Ordinal Scale is 6 or higher, the disease phase was classified as "critical".